Abstract
59 patients were treated for newly diagnosed metastatic ovarian germ cell tumours with POMB/ACE chemotherapy (which contains cisplatinum, vincristine, methotrexate, bleomycin, actinomycin D, cyclophosphamide and etoposide). The median follow-up was 7.7 years. The 3 year survival is 87.8% (95% confidence interval 76.9-93.9%) and no relapses occurred more than 3 years after treatment. 4 (7%) patients had primary drug resistance to POMB/ACE and 4 (7%) have relapsed. One patient in complete remission developed secondary acute myeloid leukaemia after receiving a total of 1.3 g/m2 etoposide. 6 of 12 (50%) patients referred at relapse were salvaged by POMB/ACE. 14 of 33 (42%) women (> 18 years old) have had successful pregnancies after fertility conserving surgery and chemotherapy with no congenital abnormalities reported. The POMB/ACE regimen is as efficacious as other published regimens for ovarian germ cell tumours (OGCT) and balances a low incidence of life-threatening toxicity with a high success rate.
MeSH terms
-
Adolescent
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Child
-
Child, Preschool
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Dactinomycin / administration & dosage
-
Dactinomycin / adverse effects
-
Etoposide / administration & dosage
-
Etoposide / adverse effects
-
Female
-
Germinoma / drug therapy*
-
Germinoma / mortality
-
Germinoma / surgery
-
Humans
-
Leucovorin / administration & dosage
-
Leucovorin / adverse effects
-
Methotrexate / administration & dosage
-
Middle Aged
-
Neoplasm Recurrence, Local
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / mortality
-
Ovarian Neoplasms / surgery
-
Pregnancy
-
Pregnancy Complications, Neoplastic
-
Remission Induction
-
Salvage Therapy
-
Survival Rate
-
Vincristine / administration & dosage
Substances
-
Bleomycin
-
Dactinomycin
-
Vincristine
-
Etoposide
-
Cyclophosphamide
-
Cisplatin
-
Leucovorin
-
Methotrexate